SHANGHAI OPM BIOSCIENCES CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.42 CNY | +1.40% |
|
-5.89% | -39.42% |
| 05-09 | OPM Biosciences' Shareholder to Cut Stake | MT |
| 04-29 | Shanghai OPM Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 8,460 | 6,332 | 3,807 | - | - |
| Enterprise Value (EV) 1 | 8,460 | 6,332 | 3,807 | 3,807 | 3,807 |
| P/E ratio | 47.9 x | 117 x | 42.8 x | 25.6 x | 17.5 x |
| Yield | - | 0.42% | 0.99% | 2.21% | 4.37% |
| Capitalization / Revenue | - | 26 x | 10.9 x | 7.61 x | 5.55 x |
| EV / Revenue | - | 26 x | 10.9 x | 7.61 x | 5.55 x |
| EV / EBITDA | - | 66.2 x | 26.8 x | 17 x | 12.7 x |
| EV / FCF | - | -323 x | 90.6 x | -1,269 x | 57.7 x |
| FCF Yield | - | -0.31% | 1.1% | -0.08% | 1.73% |
| Price to Book | - | 2.93 x | 1.74 x | 1.66 x | 1.57 x |
| Nbr of stocks (in thousands) | 114,772 | 114,772 | 113,914 | - | - |
| Reference price 2 | 73.71 | 55.17 | 33.42 | 33.42 | 33.42 |
| Announcement Date | 23/02/23 | 27/02/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 243.1 | 347.8 | 500.4 | 685.6 |
| EBITDA 1 | - | 95.71 | 142 | 224 | 300 |
| EBIT 1 | - | 61.81 | 100.7 | 170.7 | 249.7 |
| Operating Margin | - | 25.42% | 28.94% | 34.11% | 36.42% |
| Earnings before Tax (EBT) 1 | - | 61.67 | 102.3 | 172 | 251 |
| Net income 1 | 105.4 | 54.04 | 89.4 | 149.9 | 218.7 |
| Net margin | - | 22.23% | 25.7% | 29.97% | 31.91% |
| EPS 2 | 1.540 | 0.4700 | 0.7800 | 1.307 | 1.907 |
| Free Cash Flow 1 | - | -19.59 | 42 | -3 | 66 |
| FCF margin | - | -8.06% | 12.07% | -0.6% | 9.63% |
| FCF Conversion (EBITDA) | - | - | 29.58% | - | 22% |
| FCF Conversion (Net income) | - | - | 46.98% | - | 30.17% |
| Dividend per Share 2 | - | 0.2300 | 0.3300 | 0.7400 | 1.460 |
| Announcement Date | 23/02/23 | 27/02/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -19.6 | 42 | -3 | 66 |
| ROE (net income / shareholders' equity) | - | 2.48% | 4.17% | 6.43% | 9.03% |
| ROA (Net income/ Total Assets) | - | - | 4.3% | 6.2% | 7.7% |
| Assets 1 | - | - | 2,079 | 2,418 | 2,841 |
| Book Value Per Share 2 | - | 18.80 | 19.20 | 20.10 | 21.20 |
| Cash Flow per Share 2 | - | 0.5000 | 1.110 | 1.200 | 2.080 |
| Capex 1 | - | 77.5 | 81 | 81 | 77 |
| Capex / Sales | - | 31.9% | 23.29% | 16.19% | 11.23% |
| Announcement Date | 23/02/23 | 27/02/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
33.42
CNY
Average target price
53.41
CNY
Spread / Average Target
+59.81%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -39.42% | 517M | |
| +2.87% | 94.22B | |
| -4.08% | 37.76B | |
| -13.64% | 32.5B | |
| +73.38% | 27.75B | |
| -11.70% | 16.13B | |
| -1.48% | 14.19B | |
| -11.67% | 11.42B | |
| +190.36% | 11.06B | |
| -52.61% | 9.09B |
- Stock Market
- Equities
- 688293 Stock
- Financials Shanghai OPM Biosciences Co., Ltd.
